Objective To discuss the clinical effects of radionuclide ⁸⁹SrCL₂ combined zoledronic acid treatment for hormone dependent breast neoplasm metastatic osteoma.

Methods Clinical data of 64 patients with hormone dependent breast neoplasm metastatic osteoma were analyzed retrospectively.All of these patients were divided into 3 groups: one group of 22 cases treated with ⁸⁹SrCL₂(⁸⁹SrCL₂ group); another group of 21 cases treated with zoledronic acid(zoledronic acid group); and the last group of 21 cases treated with ⁸⁹SrCL₂ and zoledronic acid(combination group).Then patients′ metastatic lesion curative effects, the condition of bone pain remission, quality of life and bone marrow inhibitory reaction after treatment were observed.

Results The effective rate, visual analogue scale decline rate, whole body KPS score increase rate and bone marrow inhibitory reaction rate of the ⁸⁹SrCL₂ group were 36.4%(8/22), 77.3%(17/22), 63.6%(14/22), 27.2%(6/22), and which were 33.3%(7/21), 71.4%(15/21), 52.4%(11/21), 19.0%(4/21) and 42.9%(9/21), 90.5%(19/21), 90.5%(19/21), 33.3%(7/21) in zoledronic acid group and combination group respectively.

Conclusion ⁸⁹SrCL₂ combined with zoledronic acid on treating hormone dependent breast neoplasm metastatic osteoma has significant curative effect, and can relieve pain with less adverse reactions, and the combined treatment effects are better than that of ⁸⁹SrCL₂ or zoledronic acid alone.